Capricor Therapeutics Shares Plunge 60% Ahead of FDA Review

Capricor Therapeutics Inc. (NASDAQ:CAPR) saw its shares plummet over 60% on Monday, following the release of…

Merck’s LIPFENDRA Receives FDA Approval for Cholesterol

Merck & Co. announced on Thursday that the U.S. Food and Drug Administration (FDA) approved LIPFENDRA,…